Jaguar Health (JAGX) submits an Orphan Drug Designation application to the FDA for crofelemer, a plant-based drug, for the treatment of cholera-related diarrhea. The company aims to address rare diseases with crofelemer and expects results from proof-of-concept studies for microvillus inclusion disease (MVID) and short bowel syndrome (SBS) by 2025. Crofelemer has been granted ODD for MVID and SBS by the FDA and EMA. The potential market exclusivity and development incentives for crofelemer are highlighted, targeting a significant global health issue.
Da bin ich jetzt mal gespannt, ob das Ding wirklich explodiert |